← Patent-cliff monitor small molecule EVRYSDI RISDIPLAM
Loss of exclusivity April 2041 latest FDA-listed patent expiry
Company Genentech → See this company's full patent-cliff portfolio Drug detail Brand name EVRYSDI Active ingredient RISDIPLAM Strength 5MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval February 2025 Marketing status RX
Listed patents Patent Expires Type 12122789 April 2041 substance, product 11534444 October 2038 use U-1943 12350273 October 2038 use U-1943 11827646 January 2036 use U-1943 9969754 May 2035 substance, product 9586955 February 2033 substance, product
Regulatory exclusivity Code Expires M-270 October 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.